key: cord-0800819-w4lmigl0
authors: Shawki, May Ahmed; Elsayed, Noha Salah; Mantawy, Eman M.; Said, Riham S.
title: Promising drug repurposing approach targeted for cytokine storm implicated in SARS-CoV-2 complications
date: 2021-05-31
journal: Immunopharmacology and immunotoxicology
DOI: 10.1080/08923973.2021.1931302
sha: 1ac42d60035d1af39ec571ebd8c026299f6a0e83
doc_id: 800819
cord_uid: w4lmigl0

A global threat has emerged in 2019 due to the rapid spread of Coronavirus disease (COVID-19). As of January 2021, the number of cases worldwide reached 103 million cases and 2.22 million deaths which were confirmed as the severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2). This global pandemic galvanized the scientific community to study the causative virus (SARS-CoV2) pathogenesis, transmission, and clinical symptoms. Remarkably, the most common complication associated with this disease is the cytokine storm which is responsible for COVID-19 mortality. Thus, targeting the cytokine storm with new medications is needed to hamper COVID-19 complications where the most prominent strategy for the treatment is drug repurposing. Through this strategy, several steps are skipped especially those required for testing drug safety and thus may help in reducing the dissemination of this pandemic. Accordingly, the aim of this review is to outline the pathogenesis, clinical features, and immune complications of SARS-CoV2 in addition to suggesting several repurposed drugs with their plausible mechanism of action for possible management of severe COVID-19 cases.

Coronavirus disease 2019 (COVID- 19) , severe acute respiratory syndrome (SARS)-coronavirus 2 (SARS-CoV-2), and 2019-nCoV are all names of the new b-coronavirus which appeared in China on December 2019 [1] . World Health Organization (WHO) primary identified this virus as the 2019novel coronavirus (2019-nCoV) on 12 January 2020 and then officially named the causative disease as COVID-19. However, on 11th February 2020 the Coronavirus Study Group of the international committee suggested the name to be SARS-CoV-2. A lot of questions have been raised since that date about the properties of this virus along with its transmission, pathogenesis, and ultimately its treatment.

This pandemic started when numerous pneumonia cases were detected and epidemiologically connected to the seafood wholesale market in Wuhan, China [2] . Afterwards, COVID-19 was reported in hospitalized patients after examining the bronchoalveolar-lavage fluid of three patients using virus culture, genome sequencing, and polymerase chain reaction. Then, the phylogenetic analysis of the complete genome of SARS-CoV-2 revealed that it belongs to the b-coronavirus genus [3] . The best-known members of this genus were (SARS-CoV) that appeared in China in 2002 and led to 774 deaths and Middle East respiratory syndrome coronavirus (MERS-CoV) that was identified in Saudi Arabia in 2012 with 858 reported deaths [2, 4] .

After identification of the SARS-CoV-2 in the China outbreak, Lu and his coworkers [2] examined nine patients in Wuhan hospital and discovered that this virus is a member of the subgenus Sarbecovirus and shared a similarity to two bat-derived coronavirus strains, bat-SL-CoVZC45 and bat-SL-CoVZXC21, but less related to the known human-infecting coronaviruses. Moreover, Benvenuto et al. [5] performed a phylogenetic analysis and concluded that the SARS-CoV-2 genetic sequence clustered with the 2015 bat SARS-like coronavirus sequence. Also, Wu and his coworkers [6] found 89.1% similarity between the SARS-CoV-2 and the bat corona virus which suggests the virus may spill over from animals to humans. Critically, COVID-19 severity has been associated with a cytokine storm which is considered one of the major causes of acute respiratory distress syndrome (ARDS) and widespread tissue damage resulting in multiple-organ failure [7] . Accordingly, this article has discussed the transmission, pathogenesis, and clinical features of SARS-CoV-2. Moreover, we have reviewed the mechanism underlying SARS-CoV-2induced cytokine storm to suggest some therapeutic agents that might have potential roles in hindering COVID-19 severity.

As depicted in Figure 1 (A), SARS-CoV-2 has been reported to be transmitted between humans mostly through respiratory secretions [1, 8] . However, Zhang and his coworkers [9] found that SARS-CoV-2 was spread from infected to non-infected individuals through multiple routes such as aerosol droplets, fecal-oral or body fluid route which is not a surprising finding because SARS-CoV and MERS-CoV were previously detected in the human intestine in late infections [10] . Thus, numerous agents, including clothing and beddings, could be considered as route of transmission of COVID-19 but the infection aggressiveness of this disease is related to both droplets and aerosols especially indoors [11] . Moreover, Kampf et al. [12] reported that the human coronaviruses can remain infectious for 9 days at room temperature which suggests that hospital setting can be a major source of infection. With respect to vertical transmission, previous studies showed no evidence of intrauterine or transplacental transmission from infected pregnant mothers to their fetuses [13] although the angiotensin-converting enzyme 2 (ACE2); receptor responsible for binding of SARS-CoV2, as well as the transmembrane serine protease 2 (TMPRSS2) are found in the placenta. Conversely, a recent study reported that 3.2% of pregnant mothers transmit COVID-19 to the fetus in the third trimester [14] .

Studying the pathogenesis of SARS-CoV-2 virus and its receptors in the body ( Figure 2 ) is of great help in finding the proper therapy. SARS-CoV-2 has an envelope-anchored spike protein which is responsible for its entry into the host cell where the receptor-binding domain precisely attaches to its ACE2 receptor [15] . For a complete entry of the virus, the spike protein should be primed by transmembrane protease enzyme TMPRSS2 [16] . At this stage, the patient is asymptomatic and highly infectious and the viral load is low but can be detected by nasal swabs [17] . Afterwards, the virus migrates down the respiratory tract where a fusion of the virus with epithelial cell membrane takes place with the aid of the spike (S2) protein and the RNA genome is released into the cytoplasm of the host cell. Subsequently, the genome will code for nonstructural proteins, and form replication-transcription complex in the double-membrane vesicle leading to production of a set of sub-genomic RNAs that will further code for accessory and structural proteins. At this point, clinical manifestations of the disease are identified, and the innate immune response starts. Then, the virus binds to the cell membrane to release new virions [1] . Mostly, the later propagation of viral infection occurs in 20% of the population where the virus spreads to the gas exchange units of the lung and infects alveolar type II cells. When the CoV-2 include fever, headache, vomiting, diarrhea, sore throat, dry/wet cough, fatigue, and muscle pain. Severe pneumonia, acute respiratory distress, and blood clotting are the most serious complications. Figure generated in Biorender (https://biorender.com/). virus is released from Type II cells, a pulmonary toxin is concurrently released. Pathologically, diffuse alveolar damage with fibrin rich hyaline membranes and a few multinucleated giant cells will develop [17] .

The incubation period of COVID-19 is approximately 5 days with a median duration of symptoms of 14 days (range 6-41days) [18, 19] . The length of this period mainly depends on the age and immune status of the patient. The SARS-CoV-2 virus causes variable clinical features among the patients that can range from asymptomatic or mild symptoms, including fever, cough, breathlessness, weakness, headache, myalgia, nausea/vomiting, diarrhea, and nasal congestion to severe pneumonia and ARDS requiring intensive care unit (ICU) admission and oxygen therapy [20, 21] . Nevertheless, sputum production and hemoptysis (coughing up blood) have been reported in some cases [1, 20] . On the other side, atypical symptoms such as cardiovascular or nervous system symptoms can develop which complicates the diagnosis [21] . Besides, a few patients show some dermatological symptoms such as erythematous rash and generalized urticaria in addition to acral ischemia in the form of toe cyanosis and skin blisters [22] . However, the most unusual symptoms for COVID-19 were anosmia and dysgeusia as reported by Gelardi et al. [23] . The clinical presentation of COVID-19 infection is presented in Figure 1 (B).

According to the clinical laboratory results, most SARS-CoV-2 patients show normal or decreased white blood cells and sometimes develop lymphocytopenia and thrombocytopenia. Also, most of the patients had high values of C reactive protein and some of them showed high levels of alanine aminotransferase, aspartate aminotransferase, creatine kinase, and d-dimer [20, 21] . For radiological imaging, although some cases were reported to have normal CT imaging, others were reported to have radiographic changes including multiple small patch-like shadows and interstitial changes which could develop to multiple ground-glass opacities in both lungs [21, 24] .

One of the major complications of COVID-19 is both venous and arterial thromboembolism. The reasons attributed to these fatal complications are excessive inflammatory response with a lack of oxygen in addition to diffuse intravascular coagulation [25] . Additionally, there are neurological and psychiatric complications with COVID-19 which include altered mental status, encephalopathy, and psychosis [26] . However, the most fatal complication is hypercytokinemia, also termed as a cytokine storm. Due to severe pneumonia caused by COVID-19 disease, high production of inflammatory cytokines resulted in acute lung injury and ARDS [27] due to inflammation of the alveolar membrane leading to high lung permeability and release of pulmonary fluid into air spaces [28] .

Cytokine storm is a potentially life-threatening immune phenomena emerging from massive stimulation of inflammatory signaling cascades with subsequent overproduction of inflammatory cytokines. It is considered as the foremost cause for ARDS and hence mortality in COVID-19 infection [29] . This is mainly caused by hyperactivation and dysregulation of immune cells such as T cells and macrophages which lead to massive tissue damage [27] . Normally the immune system responds to various pathogens by activation of inflammatory pathways. However, an exaggerated response leads to dysregulated and uncontrolled disease [30] .

The inflammatory pathways involve the secretion of cytokines by both innate and adaptive immune cells. At the entry of the virus inside the body, the innate immune system response starts by detecting pathogen-associated molecular patterns (PAMP). In the case of the positive-strand RNA virus, the dsRNA and 5-triphosphate-bearing RNA molecules, replication intermediates of the virus, are all PAMPs. They are sensed by the cytoplasmic RNA sensors like the retinoic acidinducible gene I (RIG-I)-like receptors composing of RIG-I, MDA5, and LGP2 [26] . Moreover, toll like receptors (TLR3 and TLR4) play a key role in the recognition of PAMPs [27] . All of these cytoplasmic sensors activate the transcription factors interferon (IFN)-regulatory factor 3 and 7 (IRF3, IRF7) and nuclear factor Kappa B (NF-kB) which lead to excretion of Type-I IFN and pro-inflammatory cytokines ( Figure 3(A,B) ). Subsequently, the Janus kinase/signal transducers and activators of transcription (JAK-STAT) signaling pathway will be activated followed by stimulation of the expression of antiviral interferon-stimulated genes (ISGs), (Figure 3 (C)). These ISGs target the viral cycle steps to block viral replication [30] . Following these events, the leukocytes and plasma proteins are recruited to the site of infection.

The most important proinflammatory cytokines produced by macrophages and mast cells are interleukin (IL)-1, tumor necrosis factor alpha (TNF-a), and IL-6 [31] . Particularly, IL-6 is a prominent inflammatory agent of ARDS which has two pathways of signal transduction as illustrated in Figure 3 . The first pathway is the classical signal transduction pathway in which IL-6 binds to its receptor IL-6R, then together they bind to the membrane protein gp130 to trigger downstream signal transduction and gene expression. The second pathway is the trans signal transduction pathway where IL-6 binds to soluble interleukin 6 receptor (sIL-6R) which is similar to IL-6R, and subsequently the complex binds to gp130. It is interesting that the trans signaling pathways are responsible for this inflammatory response associated with COVID-19, but the classic signal transduction is the protective pathways against the viral infection. The trans signaling pathway recruits macrophages, inhibit T cells apoptosis, and inhibits differentiation of regulatory T cells (Treg). As shown in Figure 3 (D), both the trans-signaling and the classic-signaling pathways of IL-6 activate the JAK/STAT pathway and the mitogen activated protein kinase (MAPK) cascade [32] . These pathways play a major role in the differentiation of T helper (Th) cells [33] . In COVID-19 disease Th1 cells are hyperactivated as evidenced by high numbers of HLADR4 and CD38 positive cells [34] . However, lymphopenia is a hallmark in early diagnosis of COVID-19 where reduced numbers of CD8 þ T cells, B cells and Natural killer (NK) cells were demonstrated [35] . The defective responses of cytotoxic T cells, B cells and NK cells toward viral eradication provokes exaggerated and protracted generation of proinflammatory mediators most notably IL-6 by Th1 cells and macrophages, thereby aggravating the hyperinflammatory syndrome [36] .

Crucially, the produced cytokines (IFN-c and TNF-a) are responsible for the clinical features of COVID-19 such as fever, headaches, dizziness, and fatigue. Moreover, IL-6 causes vascular leakage, activation of complement and the coagulation cascade which can lead ultimately to disseminated intravascular coagulation (DIC) [37] . Soy et al. (2020) reported that increasing blood viscosity by the inflammatory mediators and immunoglobulins may be the reason for DIC [38] . Indeed, clinical laboratory studies of COVID-19 patients have reported significant elevation of serum levels of proinflammatory cytokines (IL-6, IFN-c and TNF-a) especially in critically ill patients admitted to the ICU [39] . Consequently, inflammatory mediators, primarily IL-6, can serve as useful prognostic biomarkers for the severity of COVID-19 disease [40, 41] .

Given the crucial role of the cytokine storm to the tremendous morbidity and mortality rates of COVID-19 disease worldwide, investigators are examining effective medications for combating this phenomenon in order to improve the survival rates. In this regard, various anti-inflammatory drugs and immunomodulators have been proposed for their efficacy in diminishing the COVID-19 associated cytokine storm including cytokine inhibitors: IL1-b antagonist (Anakinra), IL-6 inhibitor (Tocilizumab), TNF-a inhibitor (adalimumab), Janus kinase (JAK) inhibitors (Baricitinib), chloroquine, hydroxychloroquine, and corticosteroids [42] . Nonetheless, the quest continues toward delineating optimum therapeutic agents that target various inflammatory signaling cascades implicated in the pathogenesis of COVID-19. Accordingly, in this review, we have proposed a drug repurposing approach for combating COVID-19 associated cytokine storm.

Drugs that might affect the cytokines storm in COVID-19

Statins are widely used anti-hyperlipidemic agents that act as 3-hydroxy-3-methylglutaryl coenzyme A reductase (HMG CoA-reductase) inhibitors [43] . Not only do statins lower cholesterol levels but they also have many pleiotropic effects including reduction of vascular inflammation, improvement of endothelial function, and inhibition of platelet aggregation [44] . Statins exert an anti-inflammatory effect that might decrease the release of cytokines during the cytokine storm. The inhibitory effect of statins on inflammatory cascade was confirmed in an animal model of neuronal damage where statins decreased the release of proinflammatory cytokines such as TNF-a, IL-1b, and cyclo-oxygenase enzyme (COX)-2 in a cholesterol independent mechanism through NF-jB signaling pathway inhibition [45] . Besides, a statin was reported to decrease IL-6 in a cardiac fibrosis model and hence, inhibiting the IL-6/STAT3 pathway [46] . Moreover, this anti-inflammatory effect could also enhance the effect of the statin on promoting autophagy. It has been reported that a statin plays a role in the upregulation of autophagy by modulating AKT. and blocking the mammalian target of rapamycin (mTOR)/ribosomal protein S6 kinase (P70S6K) signaling pathway and decreasing the production of IL-1b, TNFa [47] . Moreover, statins have been reported to reduce TLR4 expression in immune cells with subsequent suppression of NF-jB and its downstream proinflammatory cytokines including IL-6 and IL-1b [48] . Also, statins were observed to have a pulmonary protective effect in an in-vivo model through mitigating alveolar damage and lung inflammation caused by paraquat intoxication [49] . Therefore, statins are suggested to have a beneficial effect as an adjunctive treatment of COVID-19. Moreover, statins displayed an immunomodulatory effect attributed to the inhibition of expression of major histocompatibility complex (MHC) class II, besides modulation of antigen presentation and T-cell co-stimulation which result in reducing the inflammatory effect of Th-1 cells and increasing the production of protective Th-2 cytokines [50] In addition, statins have been reported to have an antithrombotic effect through inhibition of platelet endothelial cell adhesion molecule-1 signaling [51] . This might help in the management of microvascular pulmonary thrombosis that occurs in severe pulmonary coronavirus disease 2019 [52] . Clinically, statins demonstrated positive results in previous influenza pandemics via decreasing inflammation and negative outcomes in patients with influenza infection [53] . Furthermore, statins have been reported to reduce the mortality due to influenza virus H3N2 pandemics in 2007-2008 [54] . Also, statin users with seasonal influenza demonstrated Subsequently, the protein tumor necrosis factor (TNF) receptor-associated factor 6 (TRAF6) and TAK1 are activated which further stimulate two signaling cascades; nuclear factor jB (NF-jB) pathway and mitogen-activated protein kinase (MAPK) pathway. The IjB kinase (IKK) complex consists of the catalytic subunits; IKKa and IKKb and the regulatory subunit NEMO. TAK1 binds to the IKK complex inducing phosphorylation of IKKb allowing NF-jB translocation into the nucleus to switch on the transcription machinery of a cluster of pro-inflammatory cytokines. TAK1 also induces stimulation of MAPK family members which mediates activation of AP-1 family transcription factors that further induces expression of diverse inflammatory mediators. Furthermore, the MyD88-dependent pathway can trigger phosphorylation of IRF7 that in turn induces expression of type 1 interferon (IFN). The TRIF-dependent pathway is utilized by only a few TLRs, such as TLR3 and TLR4. Upon recruitment and binding of TRIF to TLRs, it initiates the TRAF3-dependent signaling cascade which leads to phosphorylation of IRF3 that translocates to the nucleus commencing generation of type 1 IFN-b. (C) Janus kinase/signal transducers and activators of transcription (JAK/STAT) pathway. Interferons (IFN-c) trigger activation of the JAK/STAT pathway. The activated JAKs consequently phosphorylate the major substrates, STATs prompting their dimerization and then translocation into the nucleus to stimulate the expression of antiviral interferon-stimulated genes (ISGs). (D) IL-6 trans signal transduction pathway. IL-6 binds to soluble interleukin 6 receptor (sIL-6R) and subsequently bind to gp130. The trans signaling pathway stimulates JAK/STAT pathway and MAPK cascade, and recruits the macrophages. Figure generated in Biorender (https://biorender.com/). a reduction in vasopressor use and mechanical ventilation compared to non-statin users but with no significant effect on 30-day mortality [55] .

Fibrates are another class of lipid lowering drugs via their impact on hepatic peroxisome proliferator activated receptors (PPARs) that are responsible for the regulation of lipid synthesis and secretion [56] . The activation of PPARa also leads to inhibition of NF-jB thus, reducing inflammation [57] . Moreover, PPAR agonists have been reported to exert an antiplatelet effect through inhibition of COX-1, thromboxane A2, and calcium mobilization [58] .

Fenofibrates were stated to suppress inflammation and apoptosis cascades through inactivation of NF-kB and stimulation of adenosine monophosphate-activated protein kinase (AMPK) signaling [59] . Gemfibrozil has been reported to have anti-inflammatory immunomodulatory effects through the reduction of matrix metalloproteinase (MMP)-9 and the rise in adiponectin and the anti-inflammatory cytokine IL-10 [60] . Alternatively, fibrates can have an effect on reduction of viral replication as it has been reported that the combination of oseltamivir and fenofibrate in H7N9 infected mice resulted in a reduction of the viral titer in the lung tissue together with decreased pulmonary inflammation, and prolonged survival time [61] . Thus, fibrates could be a promising candidate to counteract cytokine storm and hinder viral replication in COVID-19 patients.

Thiazolidinediones or glitazones are oral insulin sensitizing medications that are used for management of type -II diabetes mellitus with minimal risk to develop hypoglycemia [62] . The mechanism of action of glizatones is through modulation of PPARs [63] . Pioglitazone reduced the level of IL-6 in a rat model of autism [64] , and decreased the levels of proinflammatory cytokines TNF-a, IL-1b, and IL-6 in an acute pancreatitis model [65] . via PPARs activation, pioglitazone induced adiponectin leading to suppression of chemokine monocyte chemoattractant protein-1 (MCP-1) and reduced the level of transforming growth factor beta (TGF-b) in an animal model [66] . Moreover, rosiglitazone was reported to exert an anti-inflammatory effect through TLR-4 inhibition [67] . In addition, PPARs activation not only hinders the inflammatory response but is also responsible for the immunomodulatory effect of glitazones. In a multiple sclerosis model, pioglitazone has been observed to inhibit T-cell proliferation and reduce the secretion of IFN-c and TNF-a proinflammatory cytokines suggesting its potential role in ameliorating the cytokine storm in COVID-19 patients [68] Moreover, the agents exert antiplatelet effect attributed to the activation of AMPK signaling pathway making platelet less responsive to stimuli such as collagen and thrombin [69] . Consequently, the activation of AMPK and PPARs by glitazones could target multiple complications associated with the COVID-19 cytokine storm such as marked inflammatory/ immune response and coagulation, and thus they may help in decreasing the severity of cases.

Apremilast is an orally administered, inhibitor of phosphodiesterase enzyme (PDE) 4 thereby blocking degradation of intracellular cyclic adenosine monophosphate (cAMP) and modulating downstream influences on numerous intracellular signaling cascades in distinct cell types including inflammatory and immune cells [70] . It is approved in many countries for the treatment of psoriasis and psoriatic arthritis [71] . Several studies have confirmed the anti-inflammatory and immunomodulatory capabilities of apremilast; it diminishes the expression of a substantial number of pro-inflammatory cytokines and chemokines [72] . Elevation of intracellular cAMP leads to stimulating protein kinase (A) enzyme which in turn catalyzes phosphorylation of various transcription factors, such as cAMP response element binding protein (CREB) resulting in induced expression of particular genes encoding anti-inflammatory mediators such as IL-10 [73] . Activated CREB interferes with NFjB transcriptional activity leading to downregulated expression of a distinct set of NFjB-dependent proinflammatory genes such as TNF-a and IL-6 [74] . Indeed, in lipopolysaccharide (LPS)-challenged peripheral blood mononuclear cells, apremilast upregulated in vitro expression of IL-10 while downregulating the expression of several proinflammatory cytokines: TNF-a, IFN-c, IL-12 and IL-23 [75] . Furthermore, it markedly blunted the production of TNF-a, IL-7, and MMP1, MMP3, MMP13, and MMP14 in vitro in human synovial cells and also substantially ameliorated experimental arthritis [76] . Clinically, in patients with psoriatic arthritis, treatment with apremilast dramatically reduced the plasma levels of proinflammatory mediators, comprising TNFa, IL-6, IL-8, macrophage inflammatory protein (MIP)-1 b, (MCP)-1, ferritin, IL-17 and IL-23, and increased plasma levels of the anti-inflammatory cytokines; IL-10 [77] . Apremilast has been reported to have substantial effects on innate immunity in patients with recalcitrant plaque psoriasis through impeding epidermal and dermal infiltration of myeloid dendritic cell, T cells, and NK cells. Besides, it considerably abrogated inflammatory cytokines production in Th1, Th17, and Th22 pathways in psoriatic skin lesions, including IL-12/IL-23p40, IL-23p19, IL-17A, and IL-22 [78] . Strikingly, in an experimental model of ulcerative colitis in mice, apremilast showed suppressive effects on IL-6 inflammatory cytokine by impeding JAK-STAT signaling through inhibiting the phosphorylation of STATs. Moreover, phosphodiesterase (PDE)-4 inhibition by apremilast extensively hindered activation of numerous pathways such as MAPK, NF-jB, and phosphatidylinositol-3-kinase-mTOR pathways, which are implicated in the regulation of both innate and adaptive immunity [79] . Indeed, the promising anti-inflammatory properties of apremilast conferred protection against carfilzomib-induced pulmonary and vascular injuries [80] . Taken together, the anti-inflammatory and immunomodulatory effects of apremilast could have therapeutic potential in the management of Covid-19.

Cilostazol is a selective inhibitor of PDE 3 enzyme which inhibits cAMP degradation in both platelets and vascular smooth muscle cells leading ultimately to the suppression of platelet aggregation and induction of peripheral vasodilation [81] . In addition to its anti-platelet, activity, cilostazol has recently been reported to have a diversity of pharmacological properties, including anti-inflammatory, antioxidant, and anti-apoptotic effects through the cAMP-dependent and -independent pathways [82] . The antiinflammatory effect of cliostazole has been demonstrated in numerous experimental models of inflammation, through upregulation of cAMP and consequently inhibition of NF-kB. Cilostazol significantly downregulated the inflammatory biomarkers, including IL-6, TNF-a, and TGF-b in a liver fibrosis model and hence, protected against thioacetamide-induced liver fibrosis [83] . The inhibitory effects on NFjB also account for its ability to blunt generation of adhesion molecules such as MCP-1 and vascular cell adhesion molecule-1 (VCAM-1) in a culture of endothelial cells taken from a human umbilical cord [84, 85] .

Multiple molecular mechanisms are implicated in the inhibitory effects of cilostazol on NFjB signaling. It directly disrupts TLR-4 and TLR-3 ligand-stimulated NF-jB transcriptional activity as evidenced by attenuating the recruitment and DNA binding activity of NF-jB p65 to the pro-inflammatory gene promoters in RAW264.7 macrophage cells stimulated with different TLR ligands [86] . Moreover, cilostazol blocked upstream activation of NF-kB by repressing phosphorylation of MAPKs, extracellular signal-regulated kinases 1 and 2 (ERK1/2) and c-Jun N-terminal kinase (JNK) in LPSstimulated microglial cells which further led to significant attenuation of the release of proinflammatory markers such as NO, prostaglandin E2, IL-1, TNF-a, and MCP-1 in LPS stimulated microglial cells [87] . Furthermore, cilostazol effectively mitigated the inflammatory responses in an animal model of ischemia-reperfusion injury in the kidney mainly via increasing PPAR-! transcriptional activity and expression in renal tissues, hence downregulating expression of inflammatory markers which include: IL-18, caspase-1, inducible nitric oxide synthase (iNOS), myeloperoxidase, intracellular adhesion molecule-1 (ICAM-1) and VCAM-1 [88] . These results from animal model were further confirmed by the clinical studies where cilostazol markedly diminished the expression of various inflammatory markers such as ICAM-1, VCAM-1 IL-1b, IL-6 and TNF-a in plasma of patients with thromboangiitis obliterans [89] . Alongside these anti-inflammatory effects, cilostazol has been shown to substantially modulate the immune responses by blocking differentiation of pro-inflammatory Th1 and Th17 cells and up-regulating anti-inflammatory Treg cells. This successfully ameliorated the severity of experimental autoimmune encephalomyelitis [90] . Other studies have reported that cilostazol can also decrease C-C chemokine receptor type 2 gene expression hence reduce MCP-1-induced chemotaxis and adhesion of monocytes [91] . Remarkably, cilostazol has displayed promising bronchodilator and bronchoprotective effects in humans implying its clinical usefulness in management of asthma [92] . In addition, due to its anti-platelet activity, cilostazol could aid in diminishing the thrombotic complications that increase the morbidity and mortality of Covid-19. The aforementioned date points out that cilostazol can offer therapeutic benefits for patients with Covid-19.

Retinoid compounds could regulate the immune system because of their similar action to vitamin A [93] . Currently, three generations of synthetic retinoids exist. Acitretin is an FDA-approved second generation retinoid used to treat psoriasis [94] . Retinoids bind cytosolic retinoic acid-binding protein transporting it to the nucleus where retinoids interact with retinoic acid receptor and retinoid receptor X along with binding to retinoic acid responsive elements on the DNA to regulate the transcription of several genes [95] .

Retinoids have multiple pharmacological activities including anti-inflammatory and apoptotic effects, besides inhibition of tumor promotion [96, 97] . Remarkably, retinoic acid (RA) hinders IL-6, IL-21, and IL-23 signaling that results in blocking the differentiation of naïve T cells to Th17 cells [98] . Furthermore, RA inhibits CD4 þ CD44 high cells in production of IL-4, IL-21, and IFN-! cytokines, therefore promoting the differentiation of Tregs [99] . Additionally, RA together with IL-2 and TGF-b enhance and sustain Forkhead family transcription factor (FOXP3) expression thereby further activates Tregs differentiation [100, 101] . Curiously, combination of TGF-b with IL-6 can stimulate Th17 cells. However, RA maintains the Treg-Th17 balance through blocking IL-6 signaling [99] . In addition to inhibiting inflammatory cytokines, RA stimulates the production of IL-10, an anti-inflammatory cytokine, in Tregs [102] . IL-22 is a crucial factor in tissue repair. Nevertheless, it is associated with an autoimmune response [103] . Notably, RA could regulate IL-22 function initially via enhancing IL-22 production in !d T cells and innate lymphoid cells followed by its neutralization and inactivation through attaching free IL-22 to binding a protein derived from immature dendritic cells [104] .

Recognition of viral pathogens through the innate immune response including RIG-I can stimulate innate antiviral signaling [105] . Acitretin, at clinically achievable concentrations boosts RIG-I expression and augments its signaling thus arming innate immune defense [106] . Based on antiviral, anti-inflammatory, and immunomodulatory roles of retinoids, acitretin is suggested as a promising agent to counteract CIVID-19-mediated cytokine storm.

Poly (ADP-ribose) polymerase (PARP) is a family of nuclear enzymes that have a crucial role in DNA repair. Currently, PARP is broadly involved in regulation of a wide variety of nuclear events, including the regulation of protein-nucleic acid interactions [107] . The epigenetic role of PARP occurs via 1-regulation of chromatin re-modelling, 2-functioning as a transcriptional co-regulator, 3-modulating DNA methylation, 4-poly (ADP) ribosylation of target proteins involved in gene transcription and/or 5-regulation of RNA metabolism and function [108, 109] .

PARP activation is involved in various pathophysiological conditions leading to cell necrosis and activation of signal transduction by acting as a co-activator in NF-jB-mediated transcription and stimulating the AKT pathway that contributes to the activation of a variety of inflammation-related transcription factors including activator protein-1(AP1), activator protein-2 (AP2), and STAT1 [110] . In this context, PARP inhibitors were reported to inhibit the overproduction of proinflammatory cytokines such as IL-6, pro-IL-1, ICAM-1, TNF-a, COX-2, iNOS, MIP-1a and MIP-2 [111] .

Olaparib is the first PARP inhibitor approved by the US Food and Drug Administration for the treatment of ovarian cancer [112] . Most of the effects of olaparib are due to the inhibition of PARP1, PARP2, and other PARP isoforms [108] . Olaparib has demonstrated cytoprotective efficacy in preclinical studies of acute lung injury and chronic asthma [113, 114] . In addition, the immunomodulatory role of Olaparib is mediated by reducing the production of Th2 cytokines in human CD4þ T-cells besides increasing Treg cells. Accordingly, the repurposing of olaparib with a short administration duration could offer beneficial outcomes for COVID-19 patients who have a high risk of mortality.

Histone deacetylases (HDACs) are a class of enzymes that remove the acetyl moiety from specific lysine residues on histone proteins leading to the tight wrapping of DNA. Therefore, HDACs act as key epigenetic modulators of essentially biological processes including transcription factors, chaperones and signaling molecules, resulting in changes in protein stability, protein-protein interactions, and protein-DNA interactions to control diverse cell functions [115, 116] .

Vorinostat is the most widely used of the HDAC inhibitors (HDACs) that target HDACs I and II and is approved for the treatment of cutaneous T cell lymphomas with good oral bioavailability and tolerability [117] . In addition to their anticancer role, HDACis are novel therapeutic tools in the management of viral infections through reactivating the latent virus present in infected cells, and then its clearance from cellular reservoirs through cytolysis or immune-mediated clearance, as demonstrated in human immune-deficiency virus (HIV), hepatitis C virus (HCV), and human cytomegalovirus infections [118, 119] .

Although high concentrations of vorinostat are required for anti-tumor effects, low concentrations of vorinostat can reduce the secretion of inflammatory cytokines, and thus ameliorate the cytokine storm syndrome [120] . Interestingly, HDACs such as Vorinostat modulates STAT1, STAT3, MAPKs, and NF-OEB signaling pathways [120] [121] [122] . Therefore, HDACs were approved as anti-inflammatory and cell-protective agents in various pathological conditions [123] [124] [125] . In this regard, Vorinostat significantly alleviated respiratory syncytial virus-induced airway inflammation through reducing proinflammatory cytokine production, besides decreasing neutrophil and T cell infiltration [126] . Interestingly, HDACs reduced the production of the macrophage migration inhibitory factor (MIF) which is a pro-inflammatory cytokine expressed by immune cells. MIF binds the Human Leukocyte Antigen (HLA) class II histocompatibility antigen gamma chain, CD74, causing its phosphorylation and the recruitment of CD44, which allows the activation of ERK/MAPK pathway [127] .

Strikingly, Vorinostat exhibits an immunomodulatory role [128] . Tregs express FOXP3, which activates many suppressive genes in Tregs and inhibits many effector T cell genes. HADCs could regulate Treg function through enhancing FOXP3 acetylation and hence relieve autoimmune diseases [129] . Vorinostat could enhance suppressive function of Treg to constrain Th17 cell differentiation, repress Th1 cell activities, and inhibit antigen presenting cells functions via targeting NF-OEB signaling pathways [124] . Interestingly, the function of exhausted CD8 T cells in chronic viral infection was shown to be restored upon HDACis treatment [130] . Consequently, Vorinostat is a promising agent to manage COVID-19 comorbidities via its antiviral and anti-inflammatory effects, besides its immunomodulatory role.

Pirfenidone is a novel anti-inflammatory, antifibrotic, antiproliferative medication approved for management of idiopathic pulmonary fibrosis [131] . Pirfenidone has been shown to have PPAR agonistic activity in a mouse model of nonalcoholic steatohepatitis and it also mediates potent anti-inflammatory activity [132] . It reduces the expression of several inflammatory cytokines such as IL-3 and IL-4 and downregulates IL-1b which is otherwise responsible for stimulation of fibroblast to produce platelet derived growth factor (PDGF) and TGF-b [133] . In an acute pancreatitis model, it suppressed the expression of NF-jB and hence decreased the level of TNF-a and IL-6 [134] . It also has been observed to block the activation of the nucleotide-binding oligomerization domain-like receptor with pyrin domain 3 (NLRP3) inflammasome, a mechanism involved in acute lung injury and alveolar damage in ARDS, which potentially leads to secretion of caspase protein, active IL-1b and reactive oxygen species [135] . These promising anti-inflammatory effects of pirfenidone suggest it as a possible candidate to be investigated for its capabilities for abrogating COVID-19 associated cytokine storm.

Nintedanib is a novel triple angiokinase inhibitor that acts on PDGF receptor, vascular endothelial growth factor receptor, and fibroblast growth factor receptor. Clinically, nintedanib is used for management of idiopathic pulmonary fibrosis [136] . Nintedanib decreased the inflammatory cytokines IL-6, TNF-a and TGF-b induced by bleomycin in an experimental rat model which otherwise mediated responsible for alveolar damage, thus supporting its anti-inflammatory and lung protective effect [137] . It also normalized the lung microvasculature and improved lung function [138] . These activities suggest the lung protective effect of nintedanib could be used during ARDS associated with sever COVID-19 cases.

In severe COVID-19 cases, coagulation dysfunction may occur within a few days as a result of severe inflammatory storms which can be fatal [139] . Tissue factor (TF) is primary initiator of the blood coagulation and is strongly activated by inflammatory cytokines [140] . Upregulation of TF induces fibrin deposition and thrombin generation that are crucial for inflammation [141] . Strikingly, TF-coagulation factor VIIa complex and coagulation FXa can activate protease-activated receptors (PAR)-2 signaling that has crucial roles in inflammation and is involved in autoimmune diseases like inflammatory bowel disease, autoimmune encephalitis, and multiple sclerosis [142, 143] . In the process, coagulation factor VIIa/ FXa-PAR-2 signaling activates NF-jB and MAPK, which play key roles role in cytokine production [144] . PAR-2 signaling has been reported to promote cytokine production by mouse CD4þ T cells [145] , leukocyte activation, and their recruitment toward the site of inflammation or infection. Therefore, PARs have important actions in innate and adaptive immune response and represent an attractive target for the therapy of inflammatory, infectious, or autoimmune diseases [146] .

Rivaroxaban is a novel anticoagulant approved for the prevention of stroke in patients with atrial fibrillation, and is also used for prophylaxis of deep venous thromboembolic and pulmonary embolism [147] . Rivaroxaban is a direct factor Xa inhibitor, and consequently reduces thrombin activation responsible for the induction of inflammatory processes, such as activation of microglia [148] or induction of proinflammatory cytokines (e.g. IL-1b, TNF-a) and cell adhesion molecules under different pathological conditions [149] . Besides its anticoagulant role, rivaroxaban mediated antiinflammatory effects in several experimental studies by modulating the levels of inflammatory cytokines including IL-1b, IL-6, TNF-a and MCP-1 [150] , besides decreasing MMP-9 [151] . Noteworthy, rivaroxaban was reported as a new therapeutic approach to prevent the progression of acute lung injury and atrial inflammatory fibrosis via suppression of PAR-2-NFjB signaling and inflammation [152, 153] . Thus, rivaroxaban represents a promising antithrombotic/anti-inflammatory strategy to hinder the coagulation disorders and cytokine storm implicated in the fatal complications of COVID 19.

Forskolin is a diterpene derivative extracted from the roots of the plant Coleus forskohlii. It directly stimulates adenylate cyclase enzyme thereby rising levels of cAMP in a variety of cells [154] . Forskolin exhibited anti-inflammatory activities as it could effectively mitigate inflammation in mononuclear leukocytes induced by LPS by diminishing the expression of a wide array of inflammatory cytokines including IL-6, IL-21, IL-23, and TNF-a. This anti-inflammatory effect was mainly attributed to down-regulating the TLR4/myeloid differentiation protein 88 (MyD88)/NF-jB inflammatory signaling cascades [155] . In an ischemia-reperfusion liver injury model, forskolin mediated a hepatoprotective effect by diminishing neutrophil and macrophage infiltration. These effects were associated with augmenting actions of anti-inflammatory cytokine IL-10 while repressing the generation of pro-inflammatory cytokines; TNF-a/IL-6/IL-12 [156] .

Similarly, forskolin exhibited nephroprotective properties by relieving uro-pathogenic Escherichia coli-induced pyelonephritis in mice as shown by reducing renal generation of proinflammatory mediators (TNF-; keratinocyte chemoattractant; IFN; MCP; macrophage inflammatory protein; Regulated upon Activation, Normal T Cell Expressed and Presumably Secreted (RANTES)) and renal myeloperoxidase activity [157] . Besides, it was documented that forskolin hampers the secretion of IL-1b from human macrophages by enhancing production of cAMP, which further binds to the NLRP3 protein and targets it for degradation [158] . Additionally, forskolin has been proven to have immunomodulatory effects in an experimental model of auto-immune encephalomyelitis through interruption of macrophage/microglia activation, and infiltration and production of IFN-c by CD4 T cells [159] . Furthermore, there was evidence for the bronchodilator effects of forskolin attributed to suppressing generation of various inflammatory cytokines and chemokines; NFkB-p65, IL-4, interleukin-5 (IL-5), IL-17 and ICAM-1 together with downregulation expression of MMP-9, and tissue inhibitor of metalloproteinase-1 (TIMP-1) in lung tissue by stabilizing the extracellular matrix [160] . In addition, forskolin has been shown to possess anti-platelet activity mediated by elevating levels of platelet cAMP [161] . Collectively, these data indicate that forskolin could be a potential candidate for management of COVID-19.

The recently emerging outbreak of COVID-19 was declared as a pandemic by the WHO in March 2020 poses enormous threat to the public health. Numerous critically ill patients died from devastating viral pneumonia and overwhelming inflammatory reactions where the virus triggers overproduction of substantial quantities of inflammatory cytokines in a phenomenon termed as 'cytokine storm.' These inflammatory responses are considered as prime causative factors of ARDS and multiple-organ failure associated with COVID-19 and thus contributes to disease progression. Hence, elucidating the underlying molecular mechanisms responsible for this potentially life-threatening event is challenging medical health systems worldwide. In addition, exploring effective therapeutic modalities for combating the cytokine storm represents an urgent necessity as it can provide a path forward to diminish the morbidity and mortality in COVID-19 infection. In this review, we have highlighted the pathophysiology of COVID-19 -induced cytokine storm focusing on the precise molecular mechanisms an underlying this phenomenon. Moreover, we have postulated a drug repurposing approach to be effective weapon in the battle against cytokine storm via searching the literature for drugs that can target distinct inflammatory signaling cascades implicated in the pathogenesis of cytokine storm as shown in Figure 4 . Accordingly, the discussed drugs could be promising candidates for further experimental and clinical studies investigating their therapeutic potential against COVID-19-induced cytokine storm. Summary of the discussed drugs with their potential mechanism of action in COVID-19 is presented in Table 1 .

The authors declare that there are no conflicts of interest. Anti-inflammatory effect through hindering STAT1, STAT3, MAPKs, and NF-OEB signaling pathways, besides decreasing MIF production. Immunomodulator through augmenting FOXP3 acetylation. [117, [120] [121] [122] 127, 129] Pirfenidone Management of idiopathic pulmonary fibrosis PPAR agonist. Potent anti-inflammatory and anti-fibrotic properties through inhibiting NF-jB and IL-1b signaling.

Blocking the activation of NLRP3 involved in acute lung injury.

[ [133] [134] [135] Nintedanib Management of idiopathic pulmonary fibrosis

Triple angiokinase inhibitor. Reduction the production of inflammatory cytokines. [136, 137] Rivaroxaban Anticoagulant for prevention of stroke in atrial fibrillation patients, and prophylaxis of deep venous thromboembolic and pulmonary embolism

Anti-coagulant through direct inhibition of factor Xa. Anti-inflammatory and anti-fibrotic activities through suppressing PAR-2-NF-jB signaling. [148, 152] Forskolin

No clinical data available as of yet. Direct stimulation of adenylate cyclase enzyme thus enhance the production of cAMP and degradation of NLRP3. Down-regulating the TLR4/ (MyD88)/NF-jB inflammatory signaling pathways.

Modulating immune system. Anti-platelet effect through increasing cAMP levels. 

The origin, transmission and clinical therapies on coronavirus disease 2019 (COVID-19) outbreak -an update on the status

Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding

A novel coronavirus from patients with pneumonia in China

The clinical and virological features of the first imported case causing MERS-CoV outbreak in South Korea

The 2019-new coronavirus epidemic: evidence for virus evolution

A new coronavirus associated with human respiratory disease in China

Cytokine storm and sepsis disease pathogenesis

A rapid advice guideline for the diagnosis and treatment of 2019 novel coronavirus (2019-nCoV) infected pneumonia (standard version)

Molecular and serological investigation of 2019-nCoV infected patients: implication of multiple shedding routes

Severe acute respiratory syndrome associated coronavirus is detected in intestinal tissues of fatal cases

Transmission of COVID-19 virus by droplets and aerosols: a critical review on the unresolved dichotomy

Persistence of coronaviruses on inanimate surfaces and their inactivation with biocidal agents

Clinical characteristics and intrauterine vertical transmission potential of COVID-19 infection in nine pregnant women: a retrospective review of medical records

Vertical transmission of coronavirus disease 2019: a systematic review and meta-analysis

Receptor recognition by the novel coronavirus from Wuhan: an analysis based on decadelong structural studies of SARS coronavirus

Genotype and phenotype of COVID-19: their roles in pathogenesis

Pathogenesis of COVID-19 from a cell biology perspective

The epidemiology and pathogenesis of coronavirus disease (COVID-19) outbreak

Updated understanding of the outbreak of 2019 novel coronavirus (2019-nCoV) in Wuhan

Clinical features of patients infected with 2019 novel coronavirus in Wuhan

Clinical characteristics of novel coronavirus cases in tertiary hospitals in Hubei Province

Clinical manifestations of COVID-19 in the general population: systematic review

Smell and taste dysfunction during the COVID-19 outbreak: a preliminary report

A familial cluster of pneumonia associated with the 2019 novel coronavirus indicating personto-person transmission: a study of a family cluster

Incidence of thrombotic complications in critically ill ICU patients with COVID-19

Neurological and neuropsychiatric complications of COVID-19 in 153 patients: a UKwide surveillance study

Cytokine storm intervention in the early stages of COVID-19 pneumonia

The cytokine storm in COVID-19: an overview of the involvement of the chemokine/ chemokine-receptor system

The interplay between inflammatory pathways and COVID-19: a critical review on pathogenesis and therapeutic options

Immunity to viruses

The COVID-19 cytokine storm; what we know so far

SARS-CoV-2 and COVID-19: is interleukin-6 (IL-6) the 'culprit lesion' of ARDS onset? What is there besides Tocilizumab? SGP130Fc

The role of JAK-STAT signaling pathway and its regulators in the fate of T helper cells

The pathogenesis and treatment of the Cytokine Storm' in COVID-19

The possible pathophysiology mechanism of cytokine storm in elderly adults with COVID-19 infection: the contribution of "inflame-aging

Immunopathology of Hyperinflammation in COVID-19

Immunotherapeutic implications of IL-6 blockade for cytokine storm

Cytokine storm in COVID-19: pathogenesis and overview of anti-inflammatory agents used in treatment

Targeting inflammatory cytokine storm to fight against COVID-19 associated severe complications

Deciphering the COVID-19 cytokine storm: systematic review and meta-analysis

Assessing the importance of interleukin-6 in COVID-19

Immunopathogenesis and treatment of cytokine storm in COVID-19

Statins as potential treatment for cholesterol gallstones: an attempt to understand the underlying mechanism of actions

Basic science review: statin therapy-part I: the pleiotropic effects of statins in cardiovascular disease

HMG-CoA reductase inhibitors attenuate neuronal damage by suppressing oxygen glucose deprivation-induced activated microglial cells

Atorvastatin prevents myocardial fibrosis in spontaneous hypertension via interleukin-6 (IL-6)/signal transducer and activator of transcription 3 (STAT3)/endothelin-1 (ET-1) pathway

Atorvastatin ameliorates LPSinduced inflammatory response by autophagy via AKT/mTOR signaling pathway

Effect of statins on toll-like receptors: a new insight to pleiotropic effects

Comparison of four pharmacological strategies aimed to prevent the lung inflammation and paraquat-induced alveolar damage

Regulation of different inflammatory diseases by impacting the mevalonate pathway

Antithrombotic actions of statins involve PECAM-1 signaling

Microvascular COVID-19 lung vessels obstructive thromboinflammatory syndrome (MicroCLOTS): an atypical acute respiratory distress syndrome working hypothesis

Treating influenza with statins and other immunomodulatory agents

Statin treatment and mortality: propensity score-matched analyses of

Statins and outcomes of hospitalized patients with laboratory-confirmed 2017-2018 influenza

Bethesda (MD): National Institute of Diabetes and Digestive and Kidney Diseases

Fenofibrate inhibits endothelin-1 expression by peroxisome proliferator-activated receptor alpha-dependent and independent mechanisms in human endothelial cells

Mechanism of antiplatelet action of hypolipidemic, antidiabetic and antihypertensive drugs by PPAR activation: PPAR agonists: new antiplatelet agents

Fenofibrate suppresses microvascular inflammation and apoptosis through adenosine monophosphate-activated protein kinase activation

Gemfibrozil and its combination with metformin on pleiotropic effect on IL-10 and adiponectin and anti-atherogenic treatment in insulin resistant type 2 diabetes mellitus rats

Combinations of oseltamivir and fibrates prolong the mean survival time of mice infected with the lethal H7N9 influenza virus

Understanding contemporary use of thiazolidinediones

Thiazolidinediones as antidiabetic agents: a critical review

Pioglitazone abolishes autistic-like behaviors via the IL-6 pathway

Therapeutic effect and potential mechanism of pioglitazone in rats with severe acute pancreatitis

Pioglitazone inhibits periprostatic white adipose tissue inflammation in obese mice

PPARgamma agonist rosiglitazone ameliorates LPS-induced inflammation in vascular smooth muscle cells via the TLR4/TRIF/IRF3/IP-10 signaling pathway

Anti-inflammatory and antiproliferative actions of PPAR-gamma agonists on T lymphocytes derived from MS patients

AMP-activated protein kinase mediates the antiplatelet effects of the thiazolidinediones rosiglitazone and pioglitazone

Apremilast: a novel PDE4 inhibitor in the treatment of autoimmune and inflammatory diseases

European League Against Rheumatism (EULAR) recommendations for the management of psoriatic arthritis with pharmacological therapies: 2015 update

Apremilast: a review in psoriasis and psoriatic arthritis

The cAMP signalling pathway activates CREB through PKA, p38 and MSK1 in NIH 3T3 cells

The role of the transcription factor CREB in immune function

Apremilast is a selective PDE4 inhibitor with regulatory effects on innate immunity

Apremilast, a novel PDE4 inhibitor, inhibits spontaneous production of tumour necrosis factor-alpha from human rheumatoid synovial cells and ameliorates experimental arthritis

The pharmacodynamic impact of apremilast, an oral phosphodiesterase 4 inhibitor, on circulating levels of inflammatory biomarkers in patients with psoriatic arthritis: substudy results from a phase III, randomized, placebocontrolled trial (PALACE 1)

Efficacy, tolerability, and pharmacodynamics of apremilast in recalcitrant plaque psoriasis: a phase II open-label study

Inhibition of phosphodiesterase-4 attenuates murine ulcerative colitis through interference with mucosal immunity

Apremilast ameliorates carfilzomib-induced pulmonary inflammation and vascular injuries

Anti-platelet therapy: phosphodiesterase inhibitors

Cilostazol decreases ethanol-mediated TNFalpha expression in RAW264.7 murine macrophage and in liver from binge drinking mice

The effects of increased cAMP content on inflammation, oxidative stress and PDE4 transcripts during Brucella melitensis infection

Cilostazol, a cAMP phosphodiesterase inhibitor, attenuates the production of monocyte chemoattractant protein-1 in response to tumor necrosis factor-alpha in vascular endothelial cells

Cilostazol represses vascular cell adhesion molecule-1 gene transcription via inhibiting NF-kappaB binding to its recognition sequence

Anti-inflammatory properties of cilostazol: its interruption of DNA binding activity of NF-jB from the Toll-like receptor signaling pathways

Cilostazol is anti-inflammatory in BV2 microglial cells by inactivating nuclear factor-kappaB and inhibiting mitogen-activated protein kinases

Cilostazol renoprotective effect: modulation of PPAR-c, NGAL, KIM-1 and IL-18 underlies its novel effect in a model of ischemia-reperfusion

Cilostazol on the expression of ICAM-1, VCAM-1 and inflammatory factors in plasma in patients with thromboangiitis obliterans

Suppression of encephalitogenic Tcell responses by cilostazol is associated with upregulation of regulatory T cells

Cilostazol reduces MCP-1-induced chemotaxis and adhesion of THP-1 monocytes by inhibiting CCR2 gene expression

Bronchodilator and bronchoprotective effects of cilostazol in humans in vivo

Retinoic acid and retinoic acid receptors as pleiotropic modulators of the immune system

Gene expression regulation by retinoic acid

Comparison of management guidelines for moderate-to-severe plaque psoriasis: a review of phototherapy, systemic therapies, and biologic agents

Combination therapy of sirolimus and acitretin in solid organ transplant recipients: a new cutaneous adverse event

Retinoic acid increases Foxp3þ regulatory T cells and inhibits development of Th17 cells by enhancing TGF-beta-driven Smad3 signaling and inhibiting IL-6 and IL-23 receptor expression

Retinoic acid enhances Foxp3 induction indirectly by relieving inhibition from CD4 þ CD44hi Cells

Retinoic acid can directly promote TGF-beta-mediated Foxp3(þ) Treg cell conversion of naive T cells

Vitamin A impairs the reprogramming of tregs into IL-17-producing cells during intestinal inflammation

Retinoic acid primes human dendritic cells to induce gut-homing, IL-10-producing regulatory T cells

Biological and pathological activities of interleukin-22

Interleukin-22 binding protein (IL-22BP) is constitutively expressed by a subset of conventional dendritic cells and is strongly induced by retinoic acid

RIG-I activation inhibits HIV replication in macrophages

Modulation of T cell and innate immune responses by retinoic acid

Poly-ADP-ribose polymerase: machinery for nuclear processes

Opportunities for the repurposing of PARP inhibitors for the therapy of non-oncological diseases

Poly ADP-ribose polymerase-1: beyond transcription and towards differentiation

The clinically used PARP inhibitor olaparib improves organ function, suppresses inflammatory responses and accelerates wound healing in a murine model of third-degree burn injury

Role of poly(ADP-ribose) polymerases in the regulation of inflammatory processes

Olaparib: first global approval

Pharmacological inhibition of poly (ADP-ribose) polymerase by olaparib, prevents acute lung injury associated cognitive deficits potentially through suppression of inflammatory response

PARP inhibition by olaparib alleviates chronic asthma-associated remodeling features via modulating inflammasome signaling in mice

Histone deacetylase inhibitors and the promise of epigenetic (and more) treatments for cancer

HDAC Inhibitors: novel immunosuppressants for allo-and xeno-transplantation. ChemistrySelect

Histone Deacetylases (HDACs) Guided Novel Therapies for T-cell lymphomas

Hepatitis C virus-induced oxidative stress suppresses hepcidin expression through increased histone deacetylase activity

Reactivation of latent HIV by histone deacetylase inhibitors

The antitumor histone deacetylase inhibitor suberoylanilide hydroxamic acid exhibits antiinflammatory properties via suppression of cytokines

Vorinostat modulates the imbalance of T cell subsets, suppresses macrophage activity

The histone deacetylase inhibitor ITF2357 reduces production of pro-inflammatory cytokines in vitro and systemic inflammation in vivo

Histone deacetylase inhibitors suppress inflammatory activation of rheumatoid arthritis patient synovial macrophages and tissue

Immunomodulatory effects of histone deacetylase inhibitors

Histone deacetylases and their inhibitors: new implications for asthma and chronic respiratory conditions

Histone deacetylase inhibitors suppress RSV infection and alleviate virus-induced airway inflammation

Histone deacetylase inhibitors repress macrophage migration inhibitory factor (MIF) expression by targeting MIF gene transcription through a local chromatin deacetylation

Vorinostat, a histone deacetylase inhibitor, suppresses dendritic cell function and ameliorates experimental autoimmune encephalomyelitis

Immunomodulatory effects of deacetylase inhibitors: therapeutic targeting of FOXP3þ regulatory T cells

Epigenetic manipulation restores functions of defective CD8 þ T cells from chronic viral infection

Pirfenidone for the treatment of idiopathic pulmonary fibrosis

Pirfenidone is an agonistic ligand for PPARalpha and improves NASH by activation of SIRT1/LKB1/pAMPK

Pirfenidone is a cardioprotective drug: mechanisms of action and preclinical evidence

Protective role of pirfenidone against experimentally-induced pancreatitis

Pirfenidone ameliorates lipopolysaccharide-induced pulmonary inflammation and fibrosis by blocking NLRP3 inflammasome activation

Nintedanib for idiopathic pulmonary fibrosis

The anti-fibrotic and anti-inflammatory potential of bone marrow-derived mesenchymal stem cells and nintedanib in bleomycin-induced lung fibrosis in rats

Effects of nintedanib on the microvascular architecture in a lung fibrosis model

Which lessons shall we learn from the 2019 novel coronavirus outbreak?

Regulation of tissue factor-induced signaling by endogenous and recombinant tissue factor pathway inhibitor 1

Inflammation and coagulation

Coagulation factor Xa signaling: the link between coagulation and inflammatory bowel disease?

Proteinase-activated receptor 2 modulates neuroinflammation in experimental autoimmune encephalomyelitis and multiple sclerosis

Coagulation factor Xa induces an inflammatory signalling by activation of proteaseactivated receptors in human atrial tissue

PAR-2 deficient CD4þ T cells exhibit downregulation of IL-4 and upregulation of IFN-gamma after antigen challenge in mice

Role of proteaseactivated receptors in inflammatory responses, innate and adaptive immunity

Rivaroxaban improves patency and decreases inflammation in a mouse model of catheter thrombosis

Persistent protease-activated receptor 4 signaling mediates thrombin-induced microglial activation

Thrombin and PAR-1-AP increase proinflammatory cytokine expression in C6 cells

Pretreatment with rivaroxaban attenuates stroke severity in rats by a dual antithrombotic and anti-inflammatory mechanism

Plasma proteomics of patients with non-valvular atrial fibrillation on chronic anti-coagulation with warfarin or a direct factor Xa inhibitor

Possible role of rivaroxaban in attenuating pressure-overload-induced atrial fibrosis and fibrillation

Direct factor Xa inhibition attenuates acute lung injury progression via modulation of the PAR-2/ NF-jB signaling pathway

Forskolin as a tool for examining adenylyl cyclase expression, regulation, and G protein signaling

Isoforskolin and forskolin attenuate lipopolysaccharide-induced inflammation through TLR4/MyD88/ NF-jB cascades in human mononuclear leukocytes

Activation of cyclic adenosine monophosphate-dependent protein kinase a signaling prevents liver ischemia/reperfusion injury in mice

Activation of endogenous anti-inflammatory mediator cyclic AMP attenuates acute pyelonephritis in mice induced by uropathogenic Escherichia coli

Forskolin attenuates the NLRP3 inflammasome activation and IL-1b secretion in human macrophages

Cyclic AMP Pathway Suppress Autoimmune Neuroinflammation by Inhibiting Functions of Encephalitogenic CD4 T Cells and Enhancing M2 Macrophage Polarization at the Site of Inflammation

Extracts of Coleus forskohlii relieves cough and asthma symptoms via modulating inflammation and the extracellular matrix

Effect of forskolin on platelet deaggregation and cyclic AMP generation